Navigation Links
Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
Date:2/9/2009

SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 21st Annual Roth OC Growth Stock Conference on Monday, February 16, 2009 at 1:00 p.m. PST (4:00 p.m. EST). The conference is being held at The Ritz-Carlton, Laguna Niguel.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through March 2, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepat
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
2. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
3. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
4. Bacteria from sponges make new pharmaceuticals
5. Hypertension and cholesterol medications present in water released into the St. Lawrence River
6. Sea bed provides information about present climatic change
7. David Rose to present Howe School lecture on new technologies and business models, Jan. 29
8. New manual presents robust, state-of-the-art proteomics methods for teaching and research
9. Hobbit fossils represent a new species, concludes University of Minnesota anthropologist
10. UAF researchers to present at AGU press briefing
11. New gene variants present opportunities in nutrigenomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
(Date:10/16/2014)... causes severe respiratory tract infections and worldwide claims ... at VIB and Ghent University have succeeded in ... common virus infection. , Xavier Saelens (VIB/UGent): ... the way for the development of a novel ... causes suffering in numerous small children and elderly ...
(Date:10/16/2014)... Conn. , October 16, 2014 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... its leading edge technologies including Wocket™, the Smart Wallet, ... (FiRe) Conferenece. FiRe is a leading global conference on ... Hosted by Mark Anderson , founder and ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... Sanctuary have collected the first camera trap video footage ... individuals remaining, Cross River gorillas are the world,s rarest ... by field researchers. Collected from one of four ... protected area, the footage reveals eight Cross River gorillas ...
... CUNY Energy Institute, which has been developing innovative low-cost ... discharge rates and high energy densities, announced that it ... The Institute said large-scale commercialization of the battery would ... an environmentally friendlier and less costly alternative to nickel ...
... to develop more efficient biofuel cells, seen as the future ... biological materials, they have the potential to be used indefinitely ... possible to replace a battery or recharge them. , Most ... the Leeds research will focus on bacterial enzymes that can ...
Cached Biology News:Camera trap video offers rare glimpse of world's rarest gorilla 2CUNY Energy Institute battery system could reduce buildings' electric bills 2Creating energy from light and air - new research on biofuel cells 2
(Date:10/20/2014)... Convey Computer , the leader ... Iowa State University won first place in the ... HC-2ex, the team’s solution achieved the highest overall performance ... second place finisher. , Experts from all segments of ... long challenge, using a variety of design tools, hardware ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 ... Industry Meeting (ABIM). ABIM will take ... More information about ABIM 2014 is now ... , Delegates representing companies and organizations from ... and obtain information on the latest products ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, ... Geography Trend and Forecast (2011 - 2016)," analyzes ... and studies the major market drivers, restraints, and opportunities ... Asia. , The global chocolate market is expected to ... 2016 at an estimated CAGR of 2.7% from 2011 ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... New DNA-Based Test Produces Decisive Result Within ... Enigma Diagnostics,the life sciences company developing ... it has successfully completed a project,commissioned by ... to,develop a rapid, point-of-care diagnostic system for ...
... Agreement in Principle with U.S. Attorney,s Office; ... Earnings Exceed Company Guidance;,Company Again ... Pa., Nov. 8 Cephalon, Inc. (Nasdaq:,CEPH) today reported third ... $457.2 million for the third quarter of 2006 and,within the ...
... ExonHit Therapeutics, a,drug and diagnostic discovery company, has ... test. The company expects to have,this test certified ... its GLP (Good,Laboratory Practices) compliant laboratories to the ... ExonHit test aims to identify patients suffering from,Alzheimer,s ...
Cached Biology Technology:Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme 2Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme 3Cephalon Announces Strong Third Quarter Financial Results 2Cephalon Announces Strong Third Quarter Financial Results 3Cephalon Announces Strong Third Quarter Financial Results 4Cephalon Announces Strong Third Quarter Financial Results 5Cephalon Announces Strong Third Quarter Financial Results 6Cephalon Announces Strong Third Quarter Financial Results 7Cephalon Announces Strong Third Quarter Financial Results 8Cephalon Announces Strong Third Quarter Financial Results 9Cephalon Announces Strong Third Quarter Financial Results 10Cephalon Announces Strong Third Quarter Financial Results 11Cephalon Announces Strong Third Quarter Financial Results 12Cephalon Announces Strong Third Quarter Financial Results 13Cephalon Announces Strong Third Quarter Financial Results 14Cephalon Announces Strong Third Quarter Financial Results 15Cephalon Announces Strong Third Quarter Financial Results 16Cephalon Announces Strong Third Quarter Financial Results 17Cephalon Announces Strong Third Quarter Financial Results 18ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 2ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 3ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 4
Cytofix Buffer 100 mls...
Rabbit polyclonal to JAK1 (phospho Y1022 + Y1023) ( Abpromise for all tested applications). entrezGeneID: 3716 SwissProtID: P23458...
Perm/Wash Buffer 250 Tests...
PCR purification kit, 100 preps...
Biology Products: